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A B S T R A C T
Objective: To provide an overview of prediction models for the risk of developing endometrial cancer in women
of the general population or for the presence of endometrial cancer in symptomatic women.
Methods: We systematically searched the Embase and Pubmed database until September 2017 for relevant
publications. We included studies describing the development, the external validation, or the updating of a
multivariable model for predicting endometrial cancer in the general population or symptomatic women.
Results: Out of 2756 references screened, 14 studies were included. We found two prediction models for de-
veloping endometrial cancer in the general population (risk models) and one extension. Eight studies described
the development of models for symptomatic women (diagnostic models), one comparison of the performance of
two diagnostic models and two external validation. Sample size varied from 60 (10 with cancer) to 201,811 (855
with cancer) women. The age of the women was included as a predictor in almost all models. The risk models
included epidemiological variables related to the reproductive history of women, hormone use, BMI, and
smoking history. The diagnostic models also included clinical predictors, such as endometrial thickness and
recurrent bleeding. The concordance statistic (c), assessing the discriminative ability, varied from 0.68 to 0.77 in
the risk models and from 0.73 to 0.957 in the diagnostic models. Methodological information was often limited,
especially on the handling of missing data, and the selection of predictors. One risk model and four diagnostic
models were externally validated.
Conclusions: Only a few models have been developed to predict endometrial cancer in asymptomatic or symp-
tomatic women. The usefulness of most models is unclear considering methodological shortcomings and lack of
external validation. Future research should focus on external validation and extension with new predictors or
biomarkers, such as genetic and epigenetic markers.
1. Introduction
Endometrial cancer is the sixth most common type of cancer in
women worldwide and its incidence has been increasing since 1990
(Ferlay et al., 2013). This increase might be related to improvements in
detection in the general population and in diagnostics in women with
(postmenopausal) bleeding. Further, in many populations the body
mass index (BMI) is rising and several studies have shown that adiposity
is the strongest risk factor of endometrial cancer (Kyrgiou et al., 2017;
Dixon, 2010; Collaboration NCDRF, 2016; Ng et al., 2014). Other risk
factors that are associated with endometrial cancer are higher age,
hypertension, diabetes, nulliparity, early menarche, late menopause,
oestrogen uptake, and genomic alterations (MacMahon, 1974; Hecht
and Mutter, 2006). Combining these risk factors in multivariable pre-
diction models may help to identify women in the general population at
high risk of developing endometrial cancer. Prediction models can also
facilitate early diagnosis in symptomatic women.
Several risk and diagnostics models for endometrial cancer have
been developed (Pfeiﬀer et al., 2013; Wong et al., 2016; Husing et al.,
2016; Burbos et al., 2010; Giannella et al., 2014). The models can be
used for risk prediction for prevention purposes. Particularly models
with modiﬁable risk factors, such as BMI, hypertension, and oestrogen
uptake may facilitate tailored preventive interventions on diet, lifestyle
or drug use. This might reduce the incidence of endometrial cancer.
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Once endometrial cancer has developed, diagnostic models can be used
for early diagnosis. Postmenopausal bleeding and increasing en-
dometrial thickness are the most common symptoms of endometrial
cancer and are often considered in these diagnostic models (Gull et al.,
2003). The diagnostic models facilitate early diagnosis, which may
result in eﬃcient use of diagnostic resources and improved survival.
Since no overview of these models has been published so far, we
aimed to systematically review multivariable models predicting the risk
of endometrial cancer in the general population. We also systematically
reviewed models for the presence of endometrial cancer in symptomatic
women. We describe the model development, the included predictors,
the predicted outcome, and any attempts to external validation to assess
the quality of the models and determine if these models are ready for
use in practice.
2. Methods
2.1. Search strategy
The search strategy that was used in this review was based on
previous published searches (Damen et al., 2016; Ingui and Rogers,
2001) and other systematic reviews of prediction models (Smit et al.,
2015; Meads et al., 2012; Mushkudiani et al., 2008). Speciﬁc terms for
endometrial cancer were added to the search strategy. The index terms
of papers that were considered relevant were manually searched to
check if any search terms were missing from the search strategy. The
ﬁnal strategy (S1) was used in the PubMed and Embase databases in
August 2017.
2.2. Inclusion criteria
We included all papers with the main aim of developing, validating
or updating a model predicting the risk of endometrial cancer in the
general population or presence in symptomatic women. Any multi-
variable (at least two predictors) prediction model was eligible for in-
clusion, including prediction scores or prediction tools. Only papers
written in the English language were included. There was no restriction
on publication date.
2.3. Screening process and data extraction
Two authors performed the screening process and data extraction.
One author (MA) reviewed the titles and abstracts of all papers that
were identiﬁed during the search, after which a random sample of 10%
was checked by another author (KV). Both authors independently
screened the full text of the remaining papers for eligibility.
Disagreements were solved by discussion between the authors or con-
sulting a senior author (YV).
The data extraction sheet was based on the CHARMS checklist. The
data extraction sheet was pilot tested on two articles to ensure con-
sistency between both authors. Subsequently, both authors performed
the data extraction on all included papers. Speciﬁc attention was paid
to four main topics (study design and methods, outcome and predictors,
model development, model performance and model validation) of the
CHARMS checklist, as these topics mainly inﬂuence the validity of the
models.
Study design and methods: We identiﬁed the study design (e.g. case-
control, cohort, case-cohort), source of data (e.g. hospital based or
national registries) and size of the study population. In addition, the
inclusion criteria for each study were assessed.
Outcome and predictors: We assessed the measurement and deﬁ-
nition of both the outcome and predictors, and the handling of pre-
dictors (e.g. predictors were kept continuous or were dichotomized).
Model development: We assessed the following topics: handling of
predictors, number of events per variable (EPV), number and handling
of missing data (e.g. single imputation, multiple imputation), methods
for selection of predictors in the multivariable model (e.g. univariate
analyses or subject matter knowledge) and during multivariable mod-
elling (backward or forward selection), modelling method (e.g. logistic
regression, cox proportional hazards), shrinkage (e.g. penalized
shrinkage or lasso) and model presentation (e.g. regression formula,
score chart, nomogram or risk score).
Model performance and validation: Aspects concerning model per-
formance and validation that were assessed were discrimination, cali-
bration, internal validation (e.g. split-sample approach, cross-valida-
tion, bootstrapping) and external validation (e.g. geographical or
temporal validation). Furthermore, the sensitivity, speciﬁcity, positive
and negative likelihood ratios, and positive and negative predictive
values of the diagnostic models were included in this topic, if reported.
3. Results
We identiﬁed 2756 papers during the initial search. These records
were screened on title and abstract after which 23 records were in-
cluded for full text screening. The low sensitivity of the search (less than
1% of the initial search result was included for full text screening) is in
line with other searches, as a consequence of the lack of adequate
search terms for prediction models. After full text screening, 9 papers
were eligible for inclusion. In addition, 5 extra papers were identiﬁed
by hand search, leading to the inclusion of 14 papers in this review
(Fig. 1). Two papers developed prediction models for the general po-
pulation (risk models), eight papers developed prediction models for
symptomatic women (diagnostic models), one paper internally eval-
uated a model, two papers described the external validation of previous
developed models and one paper described the extension of an existing
prediction model.
3.1. Prediction models for endometrial cancer in the general population
(risk models)
3.1.1. Study designs and population
The two studies that developed risk models used data from popu-
lation based cohorts; one study used the European EPIC cohort (Husing
et al., 2016) and one study used a cohort from the United States
(Pfeiﬀer et al., 2013) (US) (Table 1). The data was collected using a
Fig. 1. Flow diagram of study selection process.
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prospective cohort design. The sizes of the study populations were
large: 146,679 (1559 with cancer) (Pfeiﬀer et al., 2013) and 201,811
(855 with cancer) (Husing et al., 2016). Inclusion criteria were similar
for the two studies.
3.1.2. Outcome and predictors
Cases were identiﬁed through record linkage with regional cancer
registries, linkage to health insurance records, active follow-up of study
subjects and systematic requests of patient records from pathology re-
gistries in the European study (Husing et al., 2016). Identiﬁcation of
cases in the other study was done via linkage with state cancer re-
gistries, annual study updates and reviews of medical records (Pfeiﬀer
et al., 2013). Both studies included predictors that were previously
associated with endometrial cancer. The European study handled most
of the continuous predictors as a linear term and centered them at the
median (Husing et al., 2016), while the other study categorized all
continuous predictors (Pfeiﬀer et al., 2013). Both studies investigated
interaction eﬀects between predictors and had an EPV above ten.
3.1.3. Model development
Both studies encountered incomplete data. The US study created an
indicator variable for the predictor (benign breast disease) with 20%
missing data and excluded all women with missing data for other pre-
dictors (Pfeiﬀer et al., 2013). The other study used a single, simple
imputation for the missing data (Husing et al., 2016). Both prediction
models were developed with Cox proportional hazard regression for the
relative risks with an additional cause speciﬁc competing risk analysis
to enable computation of the age speciﬁc absolute risk of developing
endometrial cancer. The two studies used a stepwise backward selec-
tion procedure to identify the strongest predictors, with alpha 0.01
(Pfeiﬀer et al., 2013) and 0.1 (Husing et al., 2016). The developed
models both included the predictors age at menopause, BMI, parity,
(duration of) oral contraceptives and menopausal hormone therapy
(MHT) use, and smoking. The European model also included age at
menarche, age at ﬁrst full term pregnancy, and an interaction term
between age at menarche and BMI. The US model included an inter-
action term of MHT use and BMI < 25 kg/m2 (Table 2). The European
study used a bootstrap sample procedure followed by linear shrinkage
to improve internal validity (Husing et al., 2016).
3.1.4. Model performance and validation
The US study used independent data from the Nurses' Health Study
(NHS) to assess model performance. The validation dataset consisted of
37,241 participants and 532 cases. Performance of the risk model in the
external dataset was assessed with the c-statistic (0.68 [0.66–0.70]) and
expected versus observed ratio (E/O ratio) (1.20 [1.11–1.30])
(Table 3).
The European study used ﬁve-fold cross validation; no speciﬁcation
was given about the split of the data. The discriminative ability was
assessed with the c-statistic (0.77 [0.68–0.85]) and the calibration with
the E/O ratio (0.99) and the Hosmer-Lemeshow test (p= 0.08). The
integrated discrimination index (IDI) was also estimated (0.18% [0.04-
Table 2
Overview of predictors included in risk models and diagnostic models for endometrial cancer.
Age Age at
menopause
Age at
menarche
BMI (Duration
of) HRT use
(Duration
of) OC use
Parity Age at FFTP Menopausal
status
Smoking Biomarkers2 Recurrent
bleeding
Risk models
Fortner et al. (2017) X X X X X X X X X X X
Husing et al. (2016) X X X X X X X X X X
Pfeiﬀer et al. (2013) X X X X X X X X
Diagnostic models
Madkour (2017)
Wong et al. (2016) XX X X XX XX
Giannella et al. (2014) X X
Angioli et al. (2013) X
Opolskiene et al.
(2011)
XXX-
X
XXX
Burbos et al. (2011) X X X
Burbos et al. (2010) X X X
Weber et al. (1999) XXX X1X1 X X XXX XX
Endometri-
al thickness
Hypertension Diabetes VAS Vascularity Use of
warfarin
Ill-deﬁned
endometrium-
myometrium
interface
Irregular
endometrial
midline
Heterogeneous
endometrium
Presence of
symptoms
HE4 levels
Risk models
Fortner et al. (2017)
Husing et al. (2016)
Pfeiﬀer et al. (2013)
Diagnostic models
Madkour (2017) X X X X X
Wong et al. (2016) X
Giannella et al. (2014) X X
Angioli et al. (2013) X X X
Opolskiene et al.
(2011)
XXX X X XX
Burbos et al. (2011) X
Burbos et al. (2010) X X
Weber et al. (1999) X XXX
Abbreviations: BMI (body mass index), FFTP (ﬁrst full-term pregnancy), HRT (hormone replacement therapy), OC (oral contraceptives), VAS (visual analogue scale).
1 Weight was included as predictor instead of BMI.
2 Biomarkers included: adiponectin, oestrone, IL1Ra, TNFα and triglycerides.
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0.3]) to examine the diﬀerence between the developed model and a
model that only included age and country (Table 3).
The European model was extended with serum-based biomarkers in
a separate study (Fortner et al., 2017). The same population (EPIC
cohort) was used for updating, with a nested case-cohort design (716
participants, 247 cases). The biomarkers include adiponectin, total
cholesterol, HDL cholesterol, C-peptide, C-reactive protein, androste-
nedione, DHEAS, oestrone, glucose, IGFBP1, IGFBP2, IL1Ra, IL6, SHBG,
testosterone, TNF receptor 1, TNF receptor 2, TNFα and triglycerides.
The biomarkers were log2-transformed and adjusted for age, center and
menopausal status. Missing data was imputed with mean values. A
backward selection procedure with alpha 0.157 was used to select
serum-based biomarkers. The improvement of the model was assessed
with the c-statistic and showed 0.02 points improvement (from 0.627 to
0.647, corrected for optimism) for the model with all biomarkers, and
0.017 points improvement (from 0.627 to 0.644, corrected for opti-
mism) for the model with selected biomarkers (Table 3).
3.2. Prediction models for endometrial cancer for symptomatic women
(diagnostic models)
3.2.1. Study designs and population
Seven out of eight studies developed diagnostic models in cohorts
from Europe (n= 5), the Middle East (n=1) or Hong Kong (n=1).
One study used a case-control design for model development with
participants from the US (Weber et al., 1999) (Table 1). Population size
varied considerably between studies, from 60 (10 cases) to 4383 (168
cases). Seven studies included women presenting with postmenopausal
bleeding. Postmenopausal bleeding was in four studies deﬁned as va-
ginal bleeding after at least one year of spontaneous amenorrhoea
(Burbos et al., 2010, 2011; Opolskiene et al., 2011; Sladkevicius and
Valentin, 2016). Two studies extended this deﬁnition with a minimum
age of 40 years (Giannella et al., 2014; Madkour, 2017) and one study
did not specify any deﬁnition (Wong et al., 2016). Two studies only
included women with postmenopausal bleeding and endometrial
thickness larger than 4mm (Giannella et al., 2014) or 4.5 mm
(Opolskiene et al., 2011). One study included women aged 40–65 years
with ultrasound endometrial abnormalities (endometrial thickness,
polyps and submucous myoma) and scheduled hysteroscopy (Angioli
et al., 2013).
3.2.2. Outcome and predictors
The diagnosis of endometrial cancer in all studies was based on
histopathology of the tissue that was obtained during endometrial
sampling. Two studies restricted endometrial sampling to women with
endometrial thickness over 5mm, based on transvaginal ultrasonic
scanning (Burbos et al., 2010, 2011).
All studies included age as predictor in the multivariable modelling,
complemented with epidemiological predictors, such as BMI and parity,
or clinical predictors such as endometrial thickness and the presence of
hypertension. One study also included HE4 (Human Epididymis Protein
4) levels, a tumour marker that can be obtained via a blood test. Six out
of eight studies had an EPV of more than ten, the other studies had an
EPV of 8 (Weber et al., 1999) and below 1 (Madkour, 2017). Con-
tinuous predictors were kept continuous in seven studies (Wong et al.,
2016; Burbos et al., 2010; Giannella et al., 2014; Weber et al., 1999;
Burbos et al., 2011; Opolskiene et al., 2011; Angioli et al., 2013), one
study dichotomized the continuous predictors (Madkour, 2017).
3.2.3. Model development
Five studies (Wong et al., 2016; Burbos et al., 2010; Weber et al.,
1999; Burbos et al., 2011; Opolskiene et al., 2011) mentioned the
presence of missing data, but the handling of missing data was de-
scribed in only one study (Wong et al., 2016). Wong et al. imputed the
mean for some variables and assigned the category ‘multiparous’ to
women with missing data for the variable parity, as preliminary ana-
lysis showed no signiﬁcance for this missing category. All studies used
logistic regression analyses for model development. Six studies per-
formed a preselection of predictors based on univariable analyses, with
a p-value of 0.20 (Wong et al., 2016; Weber et al., 1999) or p-value of
0.05 (Giannella et al., 2014; Opolskiene et al., 2011; Madkour, 2017;
Angioli et al., 2013). The methods and criteria for selection of pre-
dictors during multivariable modelling varied among the studies. For-
ward selection, backward selection and full model approaches were
used. Selection was based on p-values of 0.05 in ﬁve studies (Wong
et al., 2016; Giannella et al., 2014; Weber et al., 1999; Opolskiene et al.,
2011; Angioli et al., 2013). One study did not clearly report the
methods that were used during multivariable modelling (Madkour,
2017). The predictors that were included in the developed models
varied, ranging from models with mostly epidemiological predictors, to
models that only included predictors related to abnormalities of the
endometrium (Table 2).
Table 3
Model performance and validation measures.
E/O ratio Hosmer-Lemeshow test c-statistic Internal validation External validation
Risk models
Fortner et al. (2017) 0.64 [0.60–0.69] X
Husing et al. (2016) X X 0.77 [0.68–0.85] X
Pfeiﬀer et al. (2013) X 0.68 [0.66–0.70] X
Diagnostic models
Madkour (2017) 0.95
Wong et al. (2016) 0.71 [0.66–0.75] X
0.93 [0.90–0.95] X
Giannella et al. (2014) 0.88 [0.84–0.91] X
Angioli et al. (2013) 0.957 [0.91–0.98] X X2
Opolskiene et al. (2011) 0.74 [0.67–0.81]
0.82 [0.76–0.87]
0.89 [0.84–0.94]
0.91 [0.87–0.95] X1
Burbos et al. (2011) 0.73 [0.70–0.77] X1
Burbos et al. (2010) 0.77 X
Weber et al. (1999) 0.75 X
0.74 X
0.66 X
1 = external validation was performed by Sladkevicius et al.
2 = external validation was performed by Plotti et al.
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3.2.4. Model performance and validation
Performance of the diagnostic models was assessed with measures
speciﬁc for diagnostic tests such as sensitivity and speciﬁcity (n=7),
positive and negative likelihood ratio (n= 6), positive and negative
predictive value (n= 5) and the Youden index (n=2). All studies used
the area under the ROC curve (AUC), which is the same as the c-statistic
in logistic regression analysis, to describe the discriminative ability of
the prediction model. The AUC varied from 0.73 to 0.957. The good-
ness-of-ﬁt was assessed with the Hosmer-Lemeshow test in two studiesx
(Giannella et al., 2014; Weber et al., 1999). Three studies (Wong et al.,
2016; Giannella et al., 2014; Angioli et al., 2013) used internal vali-
dation with a split-sample method, with a split into two equal parts
(Giannella et al., 2014) or in three parts (Wong et al., 2016; Angioli
et al., 2013) (two third for model development, one third for valida-
tion).
One study (Sladkevicius and Valentin, 2016) assessed the added
value of endometrial thickness to a model that included only clinical
predictors. Two external validation studies of diagnostic models were
found. Both studies were temporal validations, as data for model de-
velopment and external validation was collected in the same hospital
but data used in the validation was more recent. The authors of the
external validation studies were involved in the original model devel-
opment. Both studies used a prospective cohort to validate the devel-
oped model with sample sizes of 80 women with cancer (Sladkevicius
and Valentin, 2016) and 102 women with cancer (Plotti et al., 2017).
One study described the performance of the models in the external data
with the AUC, which was comparable to the performance in the original
data(AUC of 0.89 and 0.91 (0.91 and 0.89 in the original data respec-
tively)) (Sladkevicius and Valentin, 2016). The calibration was shown
with calibration plots, without further speciﬁcation of the intercept and
slope. One study described the model performance with the predicted
and observed number of malignant cases (93 predicted versus 102
observed) and benign cases (187 predicted versus 196 observed) and
used a predeﬁned cut-oﬀ point to determine the sensitivity, speciﬁcity,
and the positive and negative predictive value. The model showed
improved performance in terms of sensitivity (94% versus 89%) and
positive predictive value (0.91 versus 0.73).
4. Discussion
This review shows the reported prediction models for risk of en-
dometrial cancer in the general population and presence of endometrial
cancer in symptomatic women. Most models were developed and va-
lidated in European and Northern American populations. One of the
two risk models was externally validated in a large independent cohort
(Pfeiﬀer et al., 2013). Only three of the fourteen diagnostic models were
externally validated in a temporal validation study (Sladkevicius and
Valentin, 2016; Plotti et al., 2017). No head to head comparison of
developed models was found.
Age was included in almost all models; BMI and parity were also
frequently included. The risk models further included variables related
to the reproductive history of women, hormone use, and smoking. All
these predictors are known for the relation with developing en-
dometrial cancer (Smith et al., 2003; Beral et al., 2005; Lesko et al.,
1985; Hinkula et al., 2002; Kitson et al., 2017). The relation between
age and the development of several types of cancer has been most ex-
tensively described (DePinho, 2000; Balducci and Ershler, 2005;
Anisimov, 2003). In the diagnostic models clinical predictors were
more important, such as endometrial thickness, recurrent bleeding and
insulin resistance.
Shortcomings in methodology were found in almost all studies,
which is consistent with the ﬁndings from other systematic reviews on
prediction models in diﬀerent research areas (Damen et al., 2016;
Mushkudiani et al., 2008; Collins et al., 2013; Bouwmeester et al.,
2012). Information on handling of this missing data was limited. Nine
(Pfeiﬀer et al., 2013; Wong et al., 2016; Husing et al., 2016; Burbos
et al., 2010; Fortner et al., 2017; Weber et al., 1999; Burbos et al., 2011;
Opolskiene et al., 2011; Sladkevicius and Valentin, 2016) out of four-
teen studies mentioned the presence of missing data, of which four
studies (Pfeiﬀer et al., 2013; Wong et al., 2016; Husing et al., 2016;
Fortner et al., 2017) described the handling of the missing data.
Handling varied from creating an indicator variable for the missing data
to single, simple imputation. A previous simulation study has shown
that the indicator method will lead to biased results, even when the
missing data is missing completely at random (Donders et al., 2006).
None of the models used multiple imputation, while this is considered
the preferred method (Donders et al., 2006; Marshall et al., 2010).
The way of identifying the strongest predictors varied between the
models. Both forward and backward procedures were used with dif-
ferent stopping rules. The choice for a stopping rule has an inﬂuence on
the number of predictors that will be selected during the modelling
process, which may result in overﬁtting depending on the sample size
(Steyerberg, 2009). Six out of eight studies with diagnostic models
(Wong et al., 2016; Giannella et al., 2014; Weber et al., 1999;
Opolskiene et al., 2011; Madkour, 2017; Angioli et al., 2013) used a
rather stringent p-value of 0.05 during multivariable modelling, while
samples sizes were relatively small. Two of these diagnostic models had
an EPV below ten, which might contribute to overﬁtting of the pre-
diction model, resulting in too extreme predictions for new patients.
Especially the performance (c-statistic of 0.95) of the model with EPV
below 1 might be too optimistic, and will probably deteriorate during
external validation.
Reproducibility of the results can be studied with internal validation
(Steyerberg and Vergouwe, 2014). Bootstrapping is considered the most
eﬃcient method to study internal validity in small datasets (Moons
et al., 2012). Three studies (Husing et al., 2016; Fortner et al., 2017;
Weber et al., 1999) used bootstrapping to internally validate the de-
veloped models and three studies (Wong et al., 2016; Giannella et al.,
2014; Angioli et al., 2013) used a split-sample. Remarkable is the use of
bootstrapping in the EPIC study, as their sample size was large (855
women with cancer) and bootstrapping might therefore be considered
unnecessary as overﬁtting and optimism is limited in such large sample
sizes (Steyerberg, 2009).
It is important to assess the validity of a model in independent data
from a diﬀerent setting (geographical validation) or from a more recent
time period (temporal validation) (Steyerberg, 2009; Altman and
Royston, 2000; Justice et al., 1999). Three studies performed an ex-
ternal validation, in which the models showed relatively good perfor-
mance in the independent data (Pfeiﬀer et al., 2013; Sladkevicius and
Valentin, 2016; Plotti et al., 2017). One model (Pfeiﬀer et al., 2013)
overestimated the number of cases, indicating suboptimal calibration in
the large. This was related to the diﬀerence in average risk in the po-
pulation that was used for model development. Miscalibration in the
large is often found and can easily be adjusted for (te Velde et al., 2014;
Vergouwe et al., 2010).
The two risk models included in this review have moderate dis-
criminative ability, which did not improve substantially by updating
the model with serum-based biomarkers. This implies that new in-
formation may be needed to improve the model performance.
Improvement is necessary because implementing a model with poor
discriminative ability has little value in practice. New information can
for example be found in the ﬁeld of epigenetics. Current developments
in other research areas have already shown that the epigenome contains
objective information on environmental exposure and can be useful for
making risk predictions. Alterations in DNA methylation were shown to
be the consequence of adiposity. The change in DNA methylation pre-
dicted the risk of developing type 2 diabetes (Wahl et al., 2017). In
addition, the hypomethylation of the aryl hydrocarbon receptor re-
pressor (AHRR) gene holds information on former smoking status,
which might contribute to risk predictions of lung cancer (Bojesen
et al., 2017). Further, the methylation of peripheral blood cell DNA can
serve as a predictor for the risk of developing breast cancer
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(Widschwendter et al., 2008). Adding information from the epigenome
to existing risk prediction models likely improves their performance, as
information from the epigenome is less error-prone and may therefore
hold more information than data from questionnaires (Ladd-Acosta and
Fallin, 2016; Pashayan et al., 2016). Adding genetic information for
instance on mutations in mismatch repair genes, as seen in Lynch
syndrome, may also improve model performance. Women with Lynch
syndrome have approximately a 20–60% cumulative lifetime risk of
developing endometrial cancer and Lynch syndrome is responsible for
2-5% of all endometrial cancer cases (Meyer et al., 2009).
The total number of studies included in this review is relatively
small, especially the number of models that predict the risk of devel-
oping endometrial cancer in the general population. Despite extensive
searches no additional studies were found. The small number of studies
may have an inﬂuence on the overview of selected predictors, as more
studies might give a more complete and representative reﬂection of
important predictors.
In conclusion, only a few models have been developed to predict
endometrial cancer in asymptomatic or symptomatic women. The
usefulness of most of the models is unclear considering methodological
shortcomings and lack of external validation and head to head com-
parisons of models. Developed risk models should be externally vali-
dated and extended with new predictors, such as genetic and epigenetic
risk predictors, to improve model performance. Future research on di-
agnostic models should focus on external validation and creating
models with larger sample sizes, which could be realized with in-
dividual patients data meta-analysis.
S1 – Search strategy
('endometrium tumor'/exp OR (((endometri*) NEAR/3 (cancer* OR
neoplas* OR tumo* OR malign* OR carcinom* OR adenocarcinom* OR
sarcoma*))):ab,ti) AND ((“Risk function” OR 'risk assessment'/exp OR
“risk functions” OR “risk equation*” OR “risk chart*” OR (risk NEAR/3
tool*) OR “risk assessment function*” OR “risk assessor” OR “risk cal-
culation*” OR “risk calculator*” OR “risk factor* calculator*” OR “risk
factor* calculation*” OR “risk table*” OR “risk threshold*” OR “risk
scoring method*” OR “scoring scheme*” OR “risk scoring system*” OR
“risk prediction*” OR “predictive instrument*” OR “project* risk*”) OR
(('decision support system'/exp OR 'algorithm'/exp OR algorithm* OR
algorythm* OR “predictive model*” OR “prognos* model*” OR “treat-
ment decision*” OR “scoring method*” OR (prediction* NEAR/3
method*) OR (prognos* OR incidence* NEAR/3 model*)) AND ('risk
factor'/exp OR 'risk assessment'/exp OR (risk* NEAR/1 assess*) OR
“risk factor*”))) NOT ([Conference Abstract]/lim OR [Letter]/lim OR
[Note]/lim OR [Editorial]/lim).
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